Israa M. Aljnadi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Israa M. Aljnadi has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Alexandra Paulo
Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisboa, Portugal
3 shared publications - Eduarda Mendes
Research Institute for Medicines, Medicinal Chemistry Group, Faculty of Pharmacy, Universidade de Lisboa, 1649 003 Lisbon, Portugal
3 shared publications - Bruno Lourenço Victor
BioISI ‐ Biosystems and Integrative Sciences Institute Faculty of Sciences Universidade de Lisboa Campo Grande, C8 building 1749‐016 Lisboa Portugal
2 shared publications - Bárbara Bahls
Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa
2 shared publications - Rita Emídio
Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa
2 shared publications - Bárbara Bahls
Faculty of Sciences, BioISI, Biosystems and Integrative Sciences Institute, Universidade de Lisboa, 1749-016 Lisbon, Portugal
1 shared publication
Latest Publications
- Open Access
- 27 March 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Design, Synthesis and Evaluation of New Inhibitors of DNA G4 Unfolding by DHX36 helicase
The quadruplex DNA structures formed by the guanine-rich sequences (G4) present in promoter regions of oncogenes, like c-MYC, are emerging as selective anticancer drug targets, with two molecules in phase I clinical trials. G4s are dynamic structures regulating several genome processes and being regulated by helicases. Moreover, not only oncogene promoter G4s are increased in cancer cells, but also helicases are overexpressed in these cells, thus making these two genome regulators attractive targets for anticancer intervention. Herein we disclose the structure of a new small molecule with high affinity and selectivity to the cMYCG4 (Kb = 6.7 ± 0.6 x 10^6 M^-1 or KD= 0.15 ± 0.01 µM), capacity to inhibit the activity of the helicase DHX36 with Ki ~ 7 µM and antiproliferative activity in breast cancer cells overexpressing c-MYC, with IC50 values also in the low µM range. Importantly, due to the reduced number of protonable groups, this new inhibitor of DHX36-mediated G4-unfolding activity is a better drug lead molecule than the previously reported ones. The mechanism of action of this compound in breast cancer cells is now being investigated.
- 27 March 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessDesign, Synthesis and Evaluation of New Inhibitors of DNA G4 Unfolding by DHX36 helicase
The quadruplex DNA structures formed by the guanine-rich sequences (G4) present in promoter regions of oncogenes, like c-MYC, are emerging as selective anticancer drug targets, with two molecules in phase I clinical trials. G4s are dynamic structures regulating several genome processes and being regulated by helicases. Moreover, not only oncogene promoter G4s are increased in cancer cells, but also helicases are overexpressed in these cells, thus making these two genome regulators attractive targets for anticancer intervention. Herein we disclose the structure of a new small molecule with high affinity and selectivity to the cMYCG4 (Kb = 6.7 ± 0.6 x 10^6 M^-1 or KD= 0.15 ± 0.01 µM), capacity to inhibit the activity of the helicase DHX36 with Ki ~ 7 µM and antiproliferative activity in breast cancer cells overexpressing c-MYC, with IC50 values also in the low µM range. Importantly, due to the reduced number of protonable groups, this new inhibitor of DHX36-mediated G4-unfolding activity is a better drug lead molecule than the previously reported ones. The mechanism of action of this compound in breast cancer cells is now being investigated.
- Open Access
- 21 March 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (3) , 969
G-Quadruplexes in c-MYC Promoter as Targets for Cancer Therapy
Cancer is a societal burden demanding innovative approaches. A major problem with the conventional chemotherapeutic agents is their strong toxicity and other side effects due to their poor selectivity. Uncontrolled proliferation of cancer cells is due to mutations, deletions, or amplifications in genes (oncogenes) encoding for proteins that regulate cell growth and division, such as transcription factors, for example, c-MYC. The direct targeting of the c-MYC protein has been attempted but so far unsuccessfully, as it lacks a definite binding site for the modulators. Meanwhile, another approach has been explored since the discovery that G-quadruplex secondary DNA structures formed in the guanine-rich sequences of the c-MYC promoter region can downregulate the transcription of this oncogene. Here, we will overview the major achievements made in the last decades towards the discovery of a new class of anticancer drugs targeting G-quadruplexes in the c-MYC promoter of cancer cells.
- 21 March 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (3) , 969
Open AccessG-Quadruplexes in c-MYC Promoter as Targets for Cancer Therapy
Cancer is a societal burden demanding innovative approaches. A major problem with the conventional chemotherapeutic agents is their strong toxicity and other side effects due to their poor selectivity. Uncontrolled proliferation of cancer cells is due to mutations, deletions, or amplifications in genes (oncogenes) encoding for proteins that regulate cell growth and division, such as transcription factors, for example, c-MYC. The direct targeting of the c-MYC protein has been attempted but so far unsuccessfully, as it lacks a definite binding site for the modulators. Meanwhile, another approach has been explored since the discovery that G-quadruplex secondary DNA structures formed in the guanine-rich sequences of the c-MYC promoter region can downregulate the transcription of this oncogene. Here, we will overview the major achievements made in the last decades towards the discovery of a new class of anticancer drugs targeting G-quadruplexes in the c-MYC promoter of cancer cells.
- Open Access
- 28 February 2022
- Published by MDPI AG in Pharmaceuticals
- Vol. 15 (3) , 300
Major Achievements in the Design of Quadruplex-Interactive Small Molecules
Organic small molecules that can recognize and bind to G-quadruplex and i-Motif nucleic acids have great potential as selective drugs or as tools in drug target discovery programs, or even in the development of nanodevices for medical diagnosis. Hundreds of quadruplex-interactive small molecules have been reported, and the challenges in their design vary with the intended application. Herein, we survey the major achievements on the therapeutic potential of such quadruplex ligands, their mode of binding, effects upon interaction with quadruplexes, and consider the opportunities and challenges for their exploitation in drug discovery.
- 28 February 2022
- Published by MDPI AG in Pharmaceuticals
- Vol. 15 (3) , 300
Open AccessMajor Achievements in the Design of Quadruplex-Interactive Small Molecules
Organic small molecules that can recognize and bind to G-quadruplex and i-Motif nucleic acids have great potential as selective drugs or as tools in drug target discovery programs, or even in the development of nanodevices for medical diagnosis. Hundreds of quadruplex-interactive small molecules have been reported, and the challenges in their design vary with the intended application. Herein, we survey the major achievements on the therapeutic potential of such quadruplex ligands, their mode of binding, effects upon interaction with quadruplexes, and consider the opportunities and challenges for their exploitation in drug discovery.